Press Releases
  Date Title View
ROCKVILLE, Md., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance on January 31, 2017 of an eighth patent (number 9,555,004) by the United States Pat...
Posted: Feb 8, 2017
ROCKVILLE, Md., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance on January 24, 2017 of a seventh patent (number 9,549,940) by the United States Pat...
Posted: Jan 30, 2017
ROCKVILLE, Md., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company (Company) focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced that it filed with the Securities and Exchange Commission (SEC) its Quarterly Report o...
Posted: Jan 23, 2017
ROCKVILLE, Md., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the Company and host invest...
Posted: Jan 3, 2017
ROCKVILLE, Md., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the New Jersey District Court's ...
Posted: Dec 12, 2016
ROCKVILLE, Md., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today reported that, on November 14, 2016, it received a letter from the Nasdaq Listing Qualifications Dep...
Posted: Nov 17, 2016
ROCKVILLE, Md., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today provided the following business update. Commercial Update Third quarter 2016 product prescript...
Posted: Nov 14, 2016
ROCKVILLE, Md., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a business update call on Monday, November 14, 2016 at 9:00AM E...
Posted: Nov 11, 2016
ROCKVILLE, Md., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the Company and host invest...
Posted: Nov 7, 2016
Study confirms efficacy and tolerability of SPN-812, a novel non-stimulant product, in children with ADHD Study meets primary endpoint with statistically significant reduction in ADHD symptoms Conference call and webcast to discuss results at 9:00 a.m. ET, October 11, 2016 ROCKVILLE, Md., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceutical...
Posted: Oct 11, 2016
FirstPrevious
2
...
NextLast
= add release to Briefcase